Whoa, the entire PNT sector is buzzing like a cesium atom! 🧪 While the chart data is MIA, the news flow is pure rocket fuel. Defense contracts, new tech launches, and Eli Lilly's relentless pursuit of POINT Biopharma signal massive institutional belief in this space. This isn't just one deal; it's an entire ecosystem waking up. The trend vibe is aggressively bullish on the theme. Strong BUY signal on the sector narrative. #TimingIsEverything

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

POINT Biopharma Global Inc. PNT: 12.5 USD

Bullish views